Clinical Study on Grade 1 Essential Hypertension and Comparative Evaluation of Habbul Buzoor With Standard Control Drug Telmisartan in its Management.

Not yet recruiting

• Conditions: Essential (primary) hypertension,

• Registration Number: CTRI/2021/10/037024
• Lead Sponsor: Deptt of Moalejat Ajmal khan tibbiya college and hospital faculty of medicine AMU

Brief Summary

this study is randomised open parallel group comparative trial comparing the efficacy of Habbul Buzoor 750 mg twice a day with telmikind H 40mg once a day for 2 months in each group of 50 patients with Hypertension grade 1.the study is conducted in AKTCH AMU Aligarh.improvement in objective parameter will be assisted by measuring blood pressure and in subjective parameters by relief in symptoms.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-10
• Last Update Posted: 2021-09-30

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Clinically diagnosed patients of Grade 1 (According to WHO/ISH,SBP-140-159 mm of Hg and DBP-90-99 mm of Hg)2 essential hypertension on three consecutive visits under optimal conditions.
• Patients of either gender.
• Patients in the age group of 18 to 60 years.
• No evidence of target organ damage should be present.
• Patients not taking any anti-hypertensive drugs prior to state of treatment.
• Clinically stable patients.
• Those who give written consent.

Exclusion Criteria

• Patients of severe or malignant hypertension.
• Patients of Secondary hypertension.
• Patients below 18 years of age.
• Pregnant women and lactating mothers.
• Patients with unstable systemic disorders like liver,kidney or heart diseases etc.
• Patients with Clinical or laboratory evidence of target organ damage.
• Terminally ill patients like infectious diseases ,AIDS,Tuberculosis etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy will be assessed clinically by recording reading of systolic and diastolic blood pressure and relief in symptoms(if present)	2 months with every 2 week followup

Secondary Outcome Measures

Name	Time	Method
relief in symptoms(if present)

Trial Locations

Locations (1)

Ajmal Khan Tibbiya College; 🇮🇳 Aligarh, UTTAR PRADESH, India

Ajmal Khan Tibbiya College

🇮🇳Aligarh, UTTAR PRADESH, India

sadaf

Principal investigator

7417211521

sadaf68.sk@gmail.com